PROCTER-&-GAMBLE
11.3.2021 09:47:11 CET | Business Wire | Press release
Today, at the ChangeNOW online Live Talk , Procter & Gamble’s (NYSE:PG) Ariel laundry detergent brand will announce an expanded 2030 Brand Ambition focused on “reinventing clean to decarbonise laundry across its entire value chain.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210311005112/en/
To do this Ariel has focused on ensuring it can deliver a superior clean in colder water, whilst also committing the brand’s voice to encourage small habit changes such as lowering wash temperatures. The brand is also working towards establishing a sustainable supply chain with industry and suppliers, as well as partnering for innovation.
The first milestone in this journey is the roll out of Ariel’s pan-European consumer engagement campaign, “Every Degree Makes a Difference” in content partnership with National Geographic Creative Works, to demonstrate that through turning down our washing cycle temperature we can together reduce greenhouse gas emissions. The campaign, which is already launched in Germany and is coming to France this week, seeks to achieve a five degree drop in average wash temperatures in Europe by 2025.
Ariel’s Life Cycle Assessment (LCA) found that on average in Europe 60% of the environmental footprint of laundry comes when the product is being used, mainly from the energy used to heat the water. Lowering the wash temperature is the single most important thing we can all do to reduce the environmental impact of laundry. Through short films and emotive images created by National Geographic Creative Works, the campaign highlights the impact of global warming on the arctic regions and brings to life that we can all make an impact on our planet.
As part of its 2030 Ambition, Ariel is pursuing a sustainable supply chain through analysing the ingredients with highest CO2 potential in its formula and exploring alternative sourcing, working closely with its suppliers. The brand is looking into partnerships to find new solutions that help further decarbonise its value chain, including novel sources of carbon and new models for recycling.
“Serving five billion people gives our brands the unique opportunity to promote conversations, influence attitudes and change behaviour,” comments Virginie Helias, Chief Sustainability Officer at Procter & Gamble. “Ariel cleans impeccably in cold water and enables us to switch down the wash temperature when doing the laundry. With this we can all unite on the journey to decarbonise laundry across the entire value chain, helping the climate without compromising on cleaning performance.”
Ariel’s core purpose is to reinvent clean to drive progress, and its expanded Ambition announced today is underpinned by a wide range of other actions it is taking to ensure the interconnected sustainability challenges we all face are being addressed. These include circular packaging, responsibly sourced and less carbon intensive ingredients, and establishing an even more efficient supply chain among others. On the societal side, Ariel continues to advocate how laundry is not only a woman’s job, but the responsibility of everyone in the household.
Ariel is one of P&G’s leading brands, and the Brand Ambition announcement is part of the overall commitment from P&G for 100% of their leadership brands to enable and inspire responsible consumption by 2030 as part of the company’s Ambition 2030 sustainability goals.
To access images and other multimedia content, please visit here .
About Every Degree Makes a Difference Campaign
“Every Degree Makes a Difference” is a campaign being run by Ariel that aims to educate consumers on the benefits of turning their washing machines down and doing their laundry at lower temperatures. The campaign has been designed to educate consumers on the following key information: https://www.nationalgeographic.com/ariel-every-degree-makes-a-difference/
The Life Cycle Assessment of a fabric care detergent clearly signifies that the environmental footprint is only 40% product related versus up to 60% usage related at home when people use the washing machine (50% from heating the water, data is based on the average for European region).
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005112/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom